Eventide Healthcare & Life Sciences is not a bad option within its narrow niche, though most investors should approach it with caution due to its inherent volatility. It maintains its pillar scores of Above Average for People and Average for Process.
Eventide Healthcare & Life Sciences N ETNHX
- NAV / 1-Day Return 33.64 / −0.50 %
- Total Assets 1.5 Bil
-
Adj. Expense Ratio
1.510%
- Expense Ratio 1.510%
- Distribution Fee Level Above Average
- Share Class Type No Load
- Category Health
- Investment Style Small Growth
- Min. Initial Investment 1,000
- Status Open
- TTM Yield —
- Turnover 79%
USD | NAV as of Jun 11, 2024 | 1-Day Return as of Jun 11, 2024, 10:14 PM GMT+0
Morningstar’s Analysis ETNHX
Will ETNHX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 33.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Zentalis Pharmaceuticals Inc Ordinary Shares | 6.03 | 103.7 Mil | Healthcare |
Celldex Therapeutics Inc | 3.81 | 65.5 Mil | Healthcare |
Shockwave Medical Inc | 3.76 | 64.8 Mil | Healthcare |
First American Government Obligs U | 3.60 | 61.9 Mil | Cash and Equivalents |
Us Bank Mmda - Usbgfs 9 | 3.47 | 59.7 Mil | Cash and Equivalents |
Inari Medical Inc Ordinary Shares | 3.14 | 54.0 Mil | Healthcare |
Lexeo Therapeutics Inc | 3.07 | 52.8 Mil | Healthcare |
Collegium Pharmaceutical Inc | 2.90 | 49.9 Mil | Healthcare |
Crinetics Pharmaceuticals Inc | 2.88 | 49.6 Mil | Healthcare |
Korro Bio Inc | 2.81 | 48.4 Mil | Healthcare |